Clinical Trial Demonstrates Safety of Immunotherapy Drug Combinations in Small Cell and Non-Small Cell Lung Cancers

Clinical Trial Demonstrates Safety of Immunotherapy Drug Combinations in Small Cell and Non-Small Cell Lung Cancers
Clinical Trial Demonstrates Safety of Immunotherapy Drug Combinations in Small Cell and Non-Small Cell Lung Cancers

DENVER, CO—Pembrolizumab (pembro), an immunotherapy drug that unmasks cancer cells allowing the body's immune system to destroy tumors, appears to be safe in treating lung cancers, according to a study presented at the 16th World Conference on Lung Cancer..

The PembroPlus clinical trial launched in January 2014 and combines more traditional chemotherapy drugs (gemcitabine, docetaxel, nab-paclitaxel, vinorelbine, irinotecan, and/or liposomal doxorubicin) with immunotherapy (pembrolizumab), activating the body's own immune system to improve upon results that may be achieved with chemotherapy alone.

Findings from the phase Ib/II trial presented were based on the updated results from 12 patients with lung cancer who enrolled in the clinical trial with pembro and irinotecan or gemcitabine with or without vinorelbine or docetaxel.

"We found that the combination of pembrolizumab and chemotherapies evaluated thus far, in patients with advanced small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), appears to be safe," said Glen Weiss, MD, MBA, director of Clinical Research and medical oncologist at Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona, where he currently supervises more than 30 clinical trials involving hundreds of patients. "We are excited to share these initial trial results with our colleagues around the world."

The study of pembrolizumab was presented during a session on small cell lung cancer. Weiss also presented two other abstracts at the conference.

One study, in which Weiss was the senior author, highlighted the extended survival of patients with metastatic small cell lung cancer (SCLC) who received statins. The study was based on a preclinical, drug-repositioning study of 876 patients with SCLC. Statins were found to offer a survival benefit in metastatic small cell lung cancer.

Another study emphasized the enhanced antitumor activity of chemotherapy in combination with drugs that inactivate a proteasome function. The phase 1 study found that carfilzomib and irinotecan have a potential synergistic effect in SCLC and other irinotecan-sensitive cancers by allowing normal DNA damage repair and enabling normal cell-cycle death.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs